Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;24(9):1152-1158.
doi: 10.2174/0115665240253035230920041207.

Observation on the Effect of Sequentially Combined Multi-modal Artificial Liver Treatment on HBV-related Acute-on-chronic Liver Failure

Xueshi Zhou  1   2 , Youhan Miu  3 , Xiaoye Guo  2 , Jun Wang  2 , Tingting Su  2 , Hejuan Du  2 , Sen Wang  4 , Ying Zhang  2 , Yuanwang Qiu  2 , Weifeng Zhao  1
Affiliations

Observation on the Effect of Sequentially Combined Multi-modal Artificial Liver Treatment on HBV-related Acute-on-chronic Liver Failure

Xueshi Zhou et al. Curr Mol Med. 2024.

Abstract

Objective: To observe the short-term effect of sequentially combined multimodal artificial liver treatment (SCMALT) on HBV-related acute-on-chronic liver failure (HBV-ACLF).

Methods: HBV-ACLF patients 155 cases undergoing artificial liver treatment were analyzed, and they were sorted into the SCMALT group and the conventional-modal artificial liver treatment (CALT) group. The clinical data of all patients were recorded and the serum levels of interleukin-8 (IL-8), chemokine interferon-inducible protein-10 (IP-10), and interleukin-6 (IL-6) were detected. The changes in the 30-day survival rate, cytokine level, model for end-stage liver disease (MELD) score, and complications of artificial liver treatment were analyzed.

Results: After being followed up for 30 days, 104 patients survived and 51 died. At the end of the whole-course treatment, the decreases in IL-6, IP-10, and IL-8 levels and MELD scores in the SCMALT group were greater than in the CALT group. Cox regression suggested WBC (OR=1.066, 95% CI 1.012-1.123, P=0.017), AT-III activity (OR=0.935, 95% CI 0.907-0.964, p=0.000) at baseline, artificial liver treatment mode (OR=0.362, 95% CI 0.164-0.800, p=0.012), number of artificial liver treatments (OR=0.656.95% CI 0.436-0.986, p=0.043), spontaneous peritonitis (OR=0.337, 95% CI 0.165-0.689, p=0.003), and hepatic encephalopathy (OR=0.104, 95% CI 0.028-0.388, p=0.001) were independent influencing factors of 30-day survival rate. SCMALT can significantly prolong the survival period of the patient. No obvious difference was shown in the proportions of bleeding and circulation instability between the two groups (p>0.05).

Conclusion: Compared with the CALT, SCMALT can more effectively remove inflammatory mediators and reduce the MELD score in HBV-ACLF patients, which can obviously ameliorate the prognosis, with less effect on the platelet count.

Keywords: Artificial liver; MELD.; liver failure; platelet count; sequential multi-modal treatment; therapeutic effect.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Wu T.; Li J.; Shao L.; Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut 2018,67(12),2181-2191 - DOI - PubMed
    1. Bernardi M.; Moreau R.; Angeli P.; Schnabl B.; Arroyo V.; Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015,63(5),1272-1284 - DOI - PubMed
    1. Li L.J.; Zhang Y.M.; Liu X.L.; Artificial liver support system in China: A review over the last 30 years. Ther Apher Dial 2006,10(2),160-167 - DOI - PubMed
    1. Xu X.; Liu X.; Ling Q.; Artificial liver support system combined with liver transplantation in the treatment of patients with acute-on-chronic liver failure. PLoS One 2013,8(3),e58738 - DOI - PubMed
    1. Zhou L.; Chen Y.; Model selection and curative effect judgment criteria for artificial liver in the treatment of liver failure. Zhonghua Gan Zang Bing Za Zhi 2022,30(2),127-130 - PubMed

LinkOut - more resources